Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABCL575 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ABCL575 | EXPERIMENTAL | Healthy participants will receive a single dose of ABCL575 administered by subcutaneous (SC) injection |
| Placebo | PLACEBO_COMPARATOR | Healthy participants will receive a single dose of placebo administered by subcutaneous (SC) injection |
| Name | Type | Description |
|---|---|---|
| ABCL575 | BIOLOGICAL | Participants will receive SC injection of ABCL575 |
| Placebo (Normal Saline 0.9%) | BIOLOGICAL | Participants will receive SC injection of placebo (Normal Saline 0.9%) |
Inclusion Criteria: * Healthy male or female ≥ 18 and ≤ 65 years of age at the time of screening * Good general health as determined through medical history and general physical examination * Body weight ≥ 50 and ≤ 100 Kg * Body mass index (BMI) between 18.5 kg/m2 and 30.0 kg/m2 * Non- or ex-smoker...
ABCL575 is an investigational monoclonal antibody being studied in healthy volunteers. It is currently in a Phase 1 first-in-human clinical trial to evaluate its safety, tolerability, and pharmacokinetics. The drug is not approved for any condition and is in early clinical development.
ABCL575 targets OX40L, a protein involved in immune system regulation. By binding to OX40L, the antibody may modulate immune responses. This mechanism is being investigated in a Phase 1 study in healthy participants to assess its safety and pharmacological profile.
ABCL575 is being developed by AbCellera Biologics Inc., a biotechnology company listed on the NASDAQ under the ticker symbol ABCL. The company is conducting a Phase 1 clinical trial of ABCL575 in healthy volunteers in Canada.
ABCL575 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 study is a first-in-human, single-ascending-dose trial designed to evaluate the drug's safety and tolerability in healthy participants.
ABCL575 is being studied in a Phase 1 clinical trial with the identifier NCT07108894. This is a first-in-human, single-ascending-dose study in healthy participants, with an enrollment of 40 individuals. The trial is active but not recruiting, and is being conducted in Canada.
ABCL575 is an antibody that targets OX40L, but it is a distinct investigational drug. It is not known by any alternative names. The drug is being developed by AbCellera Biologics and is currently in Phase 1 testing in healthy volunteers.